Osteoporosis Treatment Market is expected to reach US$ 22.72 billion by 2031

Clinical Diagnostics Segment to Lead Osteoporosis Treatment Market During 2023–2031

According to our new research study on “Osteoporosis Treatment Market Forecast to 2031 – COVID-19 Impact and Global Analysis – by Drug Class, Type, Route of Administration, Distribution Channel, and Geography,” the market size is expected to grow from US$ 16.83 billion in 2023 to US$ 22.72 billion by 2031; it is projected to register a CAGR of 3.8% during 2023–2031. The osteoporosis treatment market growth is attributed to the increasing cases of osteoporosis due to modifications in lifestyle and growing awareness and diagnosis of osteoporosis. Growing digital health solutions are likely to offer opportunities for the market growth. However, the comorbidities and complexity associated with osteoporosis treatment hinder the market growth.

The osteoporosis treatment market includes various drugs and therapeutic modalities carefully developed to combat osteoporosis, a disease characterized by bones becoming brittle and prone to fractures. As osteoporosis is a progressive disease, initiating the treatment at an early stage can yield better results. Osteoporosis treatment involves a series of bone density tests to determine the mineral proportion in the bones. Depending on the severity of cases, osteoporosis treatment is suggested to help reduce pain, improve mobility, and reduce the risk of disability. The osteoporosis treatment market growth is driven by growing elderly population, particularly in developed regions, and increasing recognition of osteoporosis as a pressing health issue. Relentless research and development efforts are being made to introduce breakthrough and more effective interventions to treat this debilitating disease. The osteoporosis treatment market report emphasizes the key factors impacting the market and showcases the developments of prominent players.

Osteoporosis Treatment Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

Based on drug class, the market is segmented into RANKL, bisphosphonates, selective estrogen receptor modulators (SERM), hormone therapies, and others. The RANKL segment held the largest osteoporosis treatment market share in 2023. However the hormone therapies segment is predicted to register the highest CAGR during 2021–2031. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest osteoporosis treatment market share in 2023 and is estimated to register the highest CAGR during 2023–2031. Hospital pharmacies hold a significant share of the osteoporosis treatment market, primarily due to their role in acute care and patient management. They play a key role in ensuring the availability of required medication for patients undergoing inpatient treatment, which is often necessary for severe osteoporosis or after fractures. Hospital pharmacies also provide a central location for comprehensive pharmaceutical services, including medication administration, patient education, and monitoring.

Increasing R&D for New Drug Candidates to Bring New Trends in Market in Coming Years

Developing innovative drug candidates, exploring new mechanisms of action, and leveraging advances in drug delivery systems can lead to innovative therapies with greater efficacy and fewer side effects. Companies that invest in R&D to expand their product portfolio take advantage of these processes and get a competitive advantage in the growing osteoporosis treatment market.

Rani Therapeutics (a clinical-stage biotherapeutics company) developed RT-102—the RaniPill GO capsule for the treatment of osteoporosis, which contains a proprietary formulation of a human parathyroid hormone analog (1-34). In December 2022, the company achieved positive results from the 2nd part of the Phase 1 study of RT-102, with all study endpoints met. The drug was tolerated well, and no serious adverse events were noted during the study. In addition, the drug was administered with high reliability and bioavailability, comparable or even better than subcutaneous injection.

Scientists at the Van Andel Institute have identified a key cause of low bone density that may lead to improved treatments with fewer side effects for women with osteoporosis. The research found that loss of KDM5C, an epigenetic modulator, helps preserve bone mass in mice. KDM5C alters epigenetic “marks,” similar to “on” and “off” switches, to ensure the DNA instructions are used at the right time and place. The scientists established the fact that reducing KDM5C disrupted the cellular energy production in osteoclasts—cells supporting bone resorption. This, in turn, slowed the recycling process and preserved bone mass. In addition, KDM5C is significantly linked to the X chromosomes, implying that it is more active in women than in men.

A group of drug development scientists from Florida International University’s Herbert Wertheim College of Medicine collaborated with a research team from the National Center for Advancing Translational Sciences (NCATS), which is a part of the National Institutes of Health (NIH), to identify a new way for counteracting the effects of osteoporosis. The new method implies the use of oral medication (antiresorptive medications consumed as a tablet) to stimulate osteoblasts for bone formation. The researchers focused on a hormone receptor known as relaxin family peptide receptor 2 (RXFP2)—which not only plays a role in the development of reproductive organs but also in bone growth—to promote osteoblasts in producing more bone. The NCATS team had to determine the right chemical compound to activate this receptor and use robots to search for small molecules from more than 80,000 compounds before the chemists tested hundreds of variations until they found the right match. The researchers then tested on mouse models, and a marked improvement in bone density was observed. Thus, the growing demand for new and effective drugs for the treatment of osteoporosis is expected to lead to notable osteoporosis treatment market trends in the coming years.

Key players identified and evaluated while performing osteoporosis treatment market analysis are Pfizer Inc.; Amgen Inc.; Cadila Pharmaceuticals; Eli Lilly and Company; Daiichi Sankyo Company, Limited; Teva Pharmaceuticals Inc.; Asahi Kasei Corporation; Novartis AG; Chugai Pharmaceutical Co., Ltd.; and Teijin Pharma Limited, among others.

The market, by drug class, the market is segmented into calcitonin, bisphosphonates, selective estrogen receptor modulators (SERMS), PTH related anabolic, and others. The market, based on type, is bifurcated into primary osteoporosis and secondary osteoporosis. In terms of route of administration, the market is categorized into oral, injectable, and others. The market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The scope of the osteoporosis treatment market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America held the largest share of the market in 2023. The osteoporosis treatment market size in North America is projected to reach US$ 11.26 billion by 2031 from US$ 8.26 billion in 2023; the market is expected to register a CAGR of 3.9% during 2023–2031. The market in Asia Pacific is expected to record the highest CAGR during the forecast period. The market growth in this region is attributed to the rapidly aging population, particularly in countries such as Japan and China, leading to an increased prevalence of osteoporosis. Increasing health awareness contributes to higher diagnosis rates.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com